NVNO · Insider Trading
enVVeno Medical Corporation Common Stock
Every open-market purchase and sale reported by NVNO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | Francis Duhay | Director | Sell | −11 | −$123 |
| 2026-06-12 | Francis Duhay | Director | Sell | −140 | −$1.44K |
| 2026-03-13 | Francis Duhay | Director | Sell | −140 | −$1.61K |
| 2025-12-18 | Marc H. Glickman | SVP & Chief Medical Officer | J | — | — |
| 2025-12-18 | Robert Andrew Berman | Chief Executive Officer | J | — | — |
| 2025-12-18 | Hamed Alavi | Chief Technology Officer | J | −50,000 deriv. | — |
| 2025-12-15 | Robert Gray | Director | A | +135,883 deriv. | — |
| 2025-12-15 | Matthew Jenusaitis | Director | A | +135,883 deriv. | — |
| 2025-12-15 | Sanjay Shrivastava | Director | A | +135,883 deriv. | — |
| 2025-12-15 | Francis Duhay | Director | A | +135,883 deriv. | — |
| 2025-12-12 | Francis Duhay | Director | Sell | −4,900 | −$1.74K |
| 2025-09-17 | Francis Duhay | Director | Sell | −4,900 | −$4.07K |
| 2025-05-20 | Jennifer Bright | Chief Financial Officer | A | +350,000 deriv. | — |
| 2025-01-03 | Francis Duhay | Director | Buy | +81,433 | +$250.00K |
| 2025-01-02 | Robert Gray | Director | Buy | +3,500 | +$10.29K |
| 2024-12-26 | Sanjay Shrivastava | Director | Buy | +5,400 | +$15.66K |
| 2024-12-23 | Matthew Jenusaitis | Director | Buy | +9,620 | +$24.34K |
| 2024-12-20 | Hamed Alavi | Chief Technology Officer | A | +75,000 deriv. | — |
| 2024-12-20 | Matthew Jenusaitis | Director | A | +19,752 deriv. | — |
| 2024-12-20 | Francis Duhay | Director | A | +19,752 deriv. | — |
| 2024-12-20 | Robert Andrew Berman | Chief Executive Officer | A | +200,000 deriv. | — |
| 2024-12-20 | Marc H. Glickman | SVP & Chief Medical Officer | A | +75,000 deriv. | — |
| 2024-12-20 | Sanjay Shrivastava | Director | A | +19,752 deriv. | — |
| 2024-12-20 | Robert Gray | Director | A | +19,752 deriv. | — |
| 2024-12-19 | Robert Andrew Berman | Chief Executive Officer | Buy | +12,000 | +$30.60K |
| 2024-03-15 | Hamed Alavi | Chief Technology Officer | MIXED | — | −$21.92K |
| 2023-12-07 | Robert Gray | Director | A | +13,856 deriv. | — |
| 2023-12-07 | Craig Glynn | Chief Financial Officer | A | +75,000 deriv. | — |
| 2023-12-07 | Sanjay Shrivastava | Director | A | +13,856 deriv. | — |
| 2023-12-07 | Marc H. Glickman | SVP & Chief Medical Officer | A | +100,000 deriv. | — |
| 2023-12-07 | Hamed Alavi | Chief Technology Officer | A | +100,000 deriv. | — |
| 2023-12-07 | Francis Duhay | Director | A | +13,856 deriv. | — |
| 2023-12-07 | Matthew Jenusaitis | Director | A | +13,856 deriv. | — |
| 2023-12-07 | Robert Andrew Berman | Chief Executive Officer | A | +300,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Francis Duhay | Director | 2,351 | $17.56K |
| Robert Andrew Berman | Chief Executive Officer | 635 | $4.74K |
| Matthew Jenusaitis | Director | 473 | $3.53K |
| Robert Gray | Director | 319 | $2.38K |
| Sanjay Shrivastava | Director | 265 | $1.98K |
| Marc H. Glickman | SVP & Chief Medical Officer | 46 | $344 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NVNO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.